https://biospectrumindia.com/rssfeed/suppliers/platforms%20%26%20softwares platforms & softwares https://biospectrumindia.com/news/119/26968/revvity-buys-acd-labs-to-expand-its-signals-software-capabilities.html https://biospectrumindia.com/news/119/26968/revvity-buys-acd-labs-to-expand-its-signals-software-capabilities.html Mon, 24 Nov 2025 00:00:00 +0530 US-based Revvity, Inc. has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. The transaction is expected to close late in Q4 2025. ACD/Labs brings deep expertise in supporting analytical and process chemistry within pharmaceutical and chemical R&D workflows. Its industry-leading tools help scientists identify and characterize molecules, monitor purity and quality, and deliver robust production processes. Together, Revvity Signals and ACD/Labs will provide comprehensive support across the scientific workflow—from discovery and development to scale-up and manufacturing— giving scientists the ability to interpret, manage, and act on complex data with greater speed and confidence. ACD/Labs’ industry-leading tools include: Spectrus® Platform: advanced spectral analysis Percepta® Platform: AI-driven molecular property and ADMET prediction Other specialized applications: parallel and high-throughput experimentation (Katalyst D2D®), pharmaceutical chemistry, manufacturing, and controls decision support (Luminata®), and enterprise analytical data management (ADMS)   ]]> https://biospectrumindia.com/news/119/26263/waters-enhances-alliance-is-hplc-system-software.html https://biospectrumindia.com/news/119/26263/waters-enhances-alliance-is-hplc-system-software.html Wed, 18 Jun 2025 00:00:00 +0530 Waters Corporation has announced the release of version 2.0 of the Alliance iS HPLC System software, a significant advancement that provides full end-to-end traceability and enhanced data security for the industry pharmaceutical. The integration of Empower Software's secure architecture with the Alliance iS HPLC system's touchscreen will improve compliance monitoring and intuitive traceability for customers. Globally, more than 80% of new medicines have been submitted to regulatory authorities using Empower software. With this release, the Alliance iS HPLC system offers state-of-the-art touchscreen security by enabling individual, identifiable access control through user authentication. This innovation further strengthens the system's position as the smartest HPLC system available today, setting a new benchmark for traceability while improving troubleshooting and operational efficiency. It ensures uncompromised data integrity from sample to result. This integration further enhances the simplicity of the Alliance iS HPLC System, which reduces human error by up to 40% and improves QA/QC laboratory productivity with the system's innovative intelligence that handles errors before they occur. ]]> https://biospectrumindia.com/news/119/26194/sciex-sets-new-standard-in-accurate-mass-quantitation-with-zenotof-8600-system.html https://biospectrumindia.com/news/119/26194/sciex-sets-new-standard-in-accurate-mass-quantitation-with-zenotof-8600-system.html Mon, 02 Jun 2025 00:00:00 +0530 Sciex, a global leader in life science analytical technologies and operating company of Danaher Corporation, has launched the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands of species from complex samples in short acquisition times. The ZenoTOF 8600 system brings sensitive quantitation and decades of SCIEX leadership in triple quad innovation to the ZenoTOF portfolio. Innovations include: The OptiFlow Pro source, DJet ion guide, and QJet ion guide – Enables the system to generate and transmit more ions. When combined with the Zeno trap, this facilitates 10x improvement in sensitivity, compared to the ZenoTOF 7600+ system. Mass Guard technology, introduced last year on the Sciex 7500+ system – Protects the system from contamination and increases uptime. New optical detector – Allows the system to operate effectively at higher ion currents. ZT Scan DIA 2.0 – Covers a larger mass range so scientists can now quantify what was previously a struggle to identify – across all omics disciplines. ZT Scan DIA 2.0 is a transformation of the most comprehensive Sciex DIA approach. To match the data processing needs of the ZenoTOF 8600 system, the new Sciex OS software version 4.0 enhances operability with speed and automation. Automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision. This builds on the Sciex OS ecosystem, to seamlessly connect innovations in hardware and software processing. A new software collaboration this year includes that with MS-Dial, an open-source software platform designed for untargeted metabolomics and lipidomics analysis.  ]]> https://biospectrumindia.com/news/119/26110/illumina-unveils-dragen-version-4-4-software-focusing-on-oncology-applications-for-clinical-research.html https://biospectrumindia.com/news/119/26110/illumina-unveils-dragen-version-4-4-software-focusing-on-oncology-applications-for-clinical-research.html Wed, 14 May 2025 00:00:00 +0530 US-based Illumina Inc. has announced the launch of DRAGEN version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays. Additionally, DRAGEN v4.4 continues DRAGEN's best-in-class accuracy with a 30% improvement in germline structural variant calling accuracy. DRAGEN v4.4 enhancements will simplify next-generation sequencing NGS analysis for customers while expanding their capabilities. Providing labs with ready-to-use analysis applications simplifies oncology biomarker detection and reduces complexities for customers. The applications integrate with the Illumina Connected Insights platform, allowing for a fully streamlined analysis and interpretation workflow, and enabling efficient and complete discovery and clinical research solutions across a wide range of customer segments, including genetic disease, oncology, multiomics, infectious disease, and population genomics. The University Hospital of Tübingen (UHT) in Germany is among the first adopters of the latest version of DRAGEN. UHT researchers have selected DRAGEN for a first-of-its-kind study to evaluate the clinical utility of advanced secondary analysis on whole-genome germline testing. Germline testing can help identify inherited genetic mutations that increase an individual's risk of developing certain cancers or other health conditions. ]]> https://biospectrumindia.com/news/119/26085/waters-integrates-multi-angle-light-scattering-detectors-with-empower-software.html https://biospectrumindia.com/news/119/26085/waters-integrates-multi-angle-light-scattering-detectors-with-empower-software.html Tue, 06 May 2025 00:00:00 +0530 Waters Corporation has announced that its Empower software now supports biologics data collection and quality control (QC) analysis of multi-angle light scattering (MALS) and refractive index (RI) instruments in its Wyatt Technology portfolio. This integration expands the scope of critical quality attributes that a biopharmaceutical laboratory can manage with Empower Software. In addition, this advancement simplifies the process and digital footprint of collecting and submitting compliant data to regulatory authorities – from biologic drug development to quality control – and saves customers up to six months of software validation time. Empower Software is the industry's most established and compliant chromatography data system (CDS) deployed globally, submitting data for more than 80% of novel medicines to regulatory authorities. The new integration enables the use of MALS techniques in quality control for biotherapeutics, improving efficiency and readiness to comply with Good Manufacturing Practices (GMP) while reducing the amount of training required for end-users in compliant environments. The integration of the DAWN, miniDAWN and OptiLab detectors enables the measurement of more critical quality characteristics of peptides and proteins in a single pass, reducing analysis time by 20% and providing earlier insights into the stability, safety and efficacy of biologics. ]]>